Back to company overview

Vertex Pharmaceuticals, Inc. (VRTX)

Add to research
January 29, 2025Fairly valued
Compared to:

Gilead Sciences, Inc. (GILD) | Amgen, Inc. (AMGN) | Health Care Select Sector SPDR Fund (XLV)

Key takeaways
View more

Vertex Pharmaceuticals' current valuation appears fair, balancing its strong financial performance and growth prospects against potential risks. The company's leadership in the CF market, successful launch of CASGEVY, and robust pipeline provide significant upside potential, while risks such as reliance on CF medicines and regulatory challenges are partially mitigated by ongoing diversification efforts. The current valuation multiples, while above industry average, seem justified by the company's growth trajectory and market position.

  • VRTX has demonstrated strong revenue growth in recent quarters, driven by the success of its CF franchise and the early launch of CASGEVY. Revenue in Q3 2024 reached $2.77 billion, representing a 12% increase year-over-year.
  • The company's profitability is also strong, with significant growth in net income and EPS. Net income in Q3 2024 was $1.05 billion, a significant improvement from the loss of $3.59 billion in Q2 2024.
  • VRTX's aggressive business development strategy, including the $5 billion acquisition of Alpine Immune Sciences, demonstrates its ambition to expand into new therapeutic areas like autoimmune kidney diseases, but integration and execution risks remain.
  • VRTX's "5-in-5" ambition aims to launch five new products in the next five years, which could significantly expand its market reach and revenue streams.
  • Recent news highlights the successful launch of CASGEVY and the potential for new product launches in pain and other therapeutic areas, which are expected to further drive revenue growth and profitability in the coming quarters.
Evaluation summary
Add to research
View more

  1. Company Overview:

    • Vertex Pharmaceuticals, Inc. (VRTX) is a global biotechnology company focused on developing and commercializing transformative medicines for people with serious diseases, particularly in specialty markets. The company's core business model revolves around discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases.
    • VRTX's primary revenue driver is its portfolio of approved medicines for cystic fibrosis (CF), which generated the majority of its revenue in recent quarters. The company has also recently launched CASGEVY, a gene-edited cell therapy for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), which is expected to contribute significantly to future revenue growth.
    • VRTX's pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, pain, kidney disease, type 1 diabetes, and other rare diseases. The company is actively pursuing new product launches in these areas, aiming to diversify its revenue streams beyond CF.
    • For comparative analysis, VRTX is benchmarked against the Health Care Select Sector SPDR Fund (XLV) and compared to industry peers Gilead Sciences, Inc. (GILD) and Amgen, Inc. (AMGN).

  2. Financial Performance:

    • VRTX has demonstrated strong revenue growth in recent quarters, driven by the success of its CF franchise and the early launch of CASGEVY. Revenue in Q3 2024 reached $2.77 billion, representing a 12% increase year-over-year.
    • The company's profitability is also strong, with significant growth in net income and EPS. Net income in Q3 2024 was $1.05 billion, a significant improvement from the loss of $3.59 billion in Q2 2024.
    • VRTX's profitability is significantly greater than the industry average, indicating a strong ability to generate profits. The company's gross profit margin has been consistently high, averaging around 85-87% in recent quarters.
    • VRTX's Return on Assets (ROA), Return on Equity (ROE), and Return on Invested Capital (ROIC) have been improving in recent quarters, indicating improved asset utilization efficiency. However, these metrics are still below the industry average, suggesting that VRTX may have room for further improvement in this area.
    • Recent news highlights the successful launch of CASGEVY and the potential for new product launches in pain and other therapeutic areas, which are expected to further drive revenue growth and profitability in the coming quarters.

  3. Operational Efficiency:

    • VRTX's balance sheet analysis reveals a strong liquidity position, with no short-term debt and a current ratio and quick ratio greater than 1. The company's working capital has been increasing in recent quarters, indicating a strong ability to manage its short-term obligations.
    • VRTX's cash flow analysis shows a positive trend in net operating cash flow and free cash flow. The company's free cash flow margin has been increasing, indicating a strong ability to generate cash from operations.
    • VRTX's capital expenditure has been relatively low in recent quarters, indicating a focus on organic growth and efficient capital allocation. The company's depreciation trend has been stable, reflecting a well-maintained asset base.
    • VRTX has not paid dividends or repurchased shares in recent quarters, suggesting a focus on reinvesting profits back into the business for growth.
    • VRTX's liquidity ratios are significantly higher than the industry average, indicating a more conservative approach to financing. The company's debt-to-equity and leverage ratios are also significantly lower than the industry average, reflecting a strong financial position and a low level of debt.

  4. Growth Opportunities:

    • VRTX is actively pursuing market expansion through the development and launch of new products in various therapeutic areas, including pain, kidney disease, type 1 diabetes, and other rare diseases. The company's "5-in-5" ambition aims to launch five new products in the next five years, which could significantly expand its market reach and revenue streams.
    • VRTX is investing heavily in R&D, particularly in cell and genetic therapies, to develop innovative treatments for unmet medical needs. The company's R&D spending has been increasing in recent quarters, reflecting its commitment to innovation.
    • VRTX is also pursuing geographic expansion, with a focus on expanding its presence in international markets. The company's international CF sales growth has outpaced US growth in recent quarters, indicating the potential for further expansion in these markets.
    • VRTX's strategic focus areas include expanding access to CASGEVY, preparing for the potential launch of vanzacaftor triple in CF and suzetrigine in acute pain, and investing in additional manufacturing capacity for CASGEVY.
    • The company's capital allocation strategy is focused on reinvesting profits back into the business for growth, including R&D, new product launches, and market expansion.

  5. Recent Developments and Market Sentiment:

    • Recent news highlights the successful launch of CASGEVY and the potential for new product launches in pain and other therapeutic areas, which are expected to further drive revenue growth and profitability in the coming quarters.
    • The company's recent earnings call highlighted the successful End-of-Phase 2 meetings for VX-880 and the evolving regulatory environment in renal disease, suggesting a favorable path forward for key pipeline programs.
    • Analyst sentiment towards VRTX remains positive, with many analysts expecting continued growth and profitability in the coming years.
    • Overall, the market sentiment towards VRTX is positive, driven by the company's strong financial performance, robust pipeline, and potential for new product launches.

  6. Risks and Threats:

    • VRTX faces several risks and threats, including its reliance on sales of CF medicines as its primary revenue source, potential safety issues or regulatory non-compliance with marketed products, pricing pressure and reimbursement challenges for products, and the ability to attract and retain skilled personnel.
    • The company's aggressive business development strategy, including the $5 billion acquisition of Alpine Immune Sciences, presents integration and execution risks.
    • Regulatory, pricing, and reimbursement pressures continue to be key risks for VRTX, especially as it seeks to launch new products in competitive specialty markets.
    • Recent news highlights the challenges VRTX faces in securing broad reimbursement and access for CASGEVY, which could impact its future revenue growth.

  7. Valuation Analysis:

    • VRTX's valuation metrics, such as EV/EBITDA and EV/Sales, are currently higher than the industry average, reflecting the company's strong financial performance and growth potential.
    • The company's high valuation is supported by its robust pipeline, potential for new product launches, and strong cash flow generation.
    • Potential catalysts for VRTX's valuation include the successful launch of new products, positive clinical trial results, and expansion into new therapeutic areas.

  8. Price Performance:

    • VRTX's stock price has been volatile in recent months, with periods of significant outperformance followed by periods of underperformance.
    • The stock has generally outperformed the Health Care Select Sector SPDR Fund (XLV) over the long term, but has underperformed in the short term.
    • VRTX's price performance has been influenced by recent news events, including the successful launch of CASGEVY and the company's progress in its pipeline.

  9. Future Outlook:

    • VRTX's management has provided positive guidance for the future, with expectations for continued revenue growth and profitability.
    • The company's "5-in-5" ambition, with potential launches of vanzacaftor triple for CF and suzetrigine for acute pain anticipated in early 2025, is expected to drive future growth.
    • Analyst estimates for VRTX's future performance are generally positive, with many analysts expecting continued growth and profitability in the coming years.
    • Recent news and developments suggest that VRTX is well-positioned for continued growth, driven by its strong CF franchise, the successful launch of CASGEVY, and its robust pipeline of promising therapies.

  10. Summary:

    • VRTX is a high-growth biotechnology company with a strong financial position and a robust pipeline of promising therapies. The company's key strengths include its leading position in the CF market, its successful launch of CASGEVY, its strong cash flow generation, and its commitment to innovation.
    • VRTX's weaknesses include its reliance on sales of CF medicines as its primary revenue source, the challenges it faces in securing broad reimbursement and access for CASGEVY, and the potential for regulatory and pricing pressures.
    • VRTX's opportunities include the potential for new product launches in pain, kidney disease, type 1 diabetes, and other rare diseases, the expansion of its geographic reach, and the continued growth of the specialty pharmaceutical market.
    • VRTX's threats include competition from other biotechnology companies, potential safety issues or regulatory non-compliance with marketed products, and the evolving regulatory and reimbursement landscape.
    • VRTX's overall financial health is strong, with a conservative capital structure, a strong liquidity position, and a positive trend in cash flow generation.
    • Key factors for VRTX's future performance include the successful launch of new products, the progress of its pipeline, and the company's ability to navigate the evolving regulatory and reimbursement landscape.
    • Areas requiring further monitoring include the company's ability to diversify its revenue streams beyond CF, the progress of its pipeline programs, and the impact of regulatory and pricing pressures on its future profitability.
    • VRTX's investment profile is characterized by high growth potential, moderate risk, and a strong financial position. The company's robust pipeline, potential for new product launches, and strong cash flow generation make it an attractive investment for investors seeking exposure to the biotechnology sector. However, investors should be aware of the company's reliance on sales of CF medicines as its primary revenue source, the challenges it faces in securing broad reimbursement and access for CASGEVY, and the potential for regulatory and pricing pressures.
Price history
Add to research
View more
Loading...
Fundamentals
Add to research
View more
Insights
  • Vertex Pharmaceuticals is a global biotechnology company focused on developing transformative medicines for people with serious diseases, with a focus on specialty markets.
  • The company has established a leading position in the CF market with its portfolio of approved medicines, but faces the risk of over-reliance on this revenue source if it is unable to successfully diversify its pipeline.
  • The company is making significant investments in R&D, particularly in cell and genetic therapies, to expand its product offerings and address unmet needs in rare diseases.
  • Recent approvals and launches of CASGEVY for SCD and TDT represent an important milestone, but the company faces challenges in securing broad reimbursement and access for this novel therapy.
  • Vertex's aggressive business development strategy, including the $5 billion acquisition of Alpine, demonstrates its ambition to expand into new therapeutic areas like autoimmune kidney diseases, but integration and execution risks remain.
  • Regulatory, pricing, and reimbursement pressures continue to be key risks for Vertex, especially as it seeks to launch new products in competitive specialty markets.
  • Overall, Vertex appears well-positioned financially and operationally, but must navigate a complex and evolving industry landscape to successfully execute on its growth strategy and diversify its revenue streams beyond CF.
Analysis
  • Revenue - Vertex Pharmaceuticals has demonstrated strong revenue growth in recent quarters, driven by the success of its CF franchise and the early launch of CASGEVY. - The company's revenue growth is expected to continue in the coming quarters, driven by continued strength in the CF franchise and the potential launch of new products in pain and other therapeutic areas. - The company's revenue growth is significantly greater than the industry average, indicating a strong market position and competitive advantage.
    • Profitability
      • Vertex Pharmaceuticals has demonstrated strong profitability in recent quarters, with significant growth in net income and EPS.
      • The company's profitability is expected to remain strong in the coming quarters, supported by efficient cost management and continued investments in R&D and commercialization.
      • The company's profitability is significantly greater than the industry average, indicating a strong ability to generate profits.
    • Liquidity
      • Vertex Pharmaceuticals has a strong liquidity position, with no short-term debt and a current ratio and quick ratio greater than 1.
      • The company's short-term liquidity position is expected to remain strong in the coming quarters, supported by the company's strong cash flow generation.
      • The company's liquidity position is significantly less than the industry average, indicating a more conservative approach to financing.
    • Solvency
      • Vertex Pharmaceuticals has a conservative capital structure, with a low level of debt.
      • The company's long-term solvency is strong, with a low debt-to-equity ratio and a debt-to-EBITDA ratio less than 1.
      • The company's solvency is significantly less than the industry average, indicating a more conservative approach to financing.
    • Operational Efficiency
      • Vertex Pharmaceuticals is effectively managing costs and controlling expenses, leading to improved profitability.
      • The company's asset utilization efficiency is improving, as evidenced by the increasing return on average assets, return on average total equity, return on average total capital, and return on average invested capital.
    • Cash Flow Analysis
      • Vertex Pharmaceuticals has strong cash flow generation, with a positive trend in net operating cash flow and free cash flow.
      • The company's free cash flow margin has been increasing, indicating a strong ability to generate cash from operations.
      • The company's cash flow generation is significantly greater than the industry average, indicating a strong ability to generate cash from operations.
    • Risk Factors
      • The company's reliance on sales of CF medicines as its primary revenue source could be a risk if it is unable to successfully diversify its pipeline.
      • The company faces challenges in securing broad reimbursement and access for its novel therapy CASGEVY.
      • Regulatory, pricing, and reimbursement pressures continue to be key risks for Vertex, especially as it seeks to launch new products in competitive specialty markets.
    • Future Outlook
      • Vertex Pharmaceuticals is well-positioned for continued growth, driven by its strong CF franchise, the successful launch of CASGEVY, and its robust pipeline of promising therapies.
      • The company's strong financial position provides flexibility for future acquisitions and investments.
      • The company's future outlook is positive, with the potential to become a leader in the rare disease market.
Financial statements
Add to research
View more
Loading...
Public filings
Add to research
View more
  • Vertex has established a leading position in the CF market with its portfolio of approved medicines, but faces the risk of over-reliance on this revenue source if it is unable to successfully diversify its pipeline
  • The company is making significant investments in R&D, particularly in cell and genetic therapies, to expand its product offerings and address unmet needs in rare diseases
  • Recent approvals and launches of CASGEVY for SCD and TDT represent an important milestone, but the company faces challenges in securing broad reimbursement and access for this novel therapy
  • Vertex's aggressive business development strategy, including the $5 billion acquisition of Alpine, demonstrates its ambition to expand into new therapeutic areas like autoimmune kidney diseases, but integration and execution risks remain
  • Regulatory, pricing, and reimbursement pressures continue to be key risks for Vertex, especially as it seeks to launch new products in competitive specialty markets
  • Overall, Vertex appears well-positioned financially and operationally, but must navigate a complex and evolving industry landscape to successfully execute on its growth strategy and diversify its revenue streams beyond CF.

Core Business and Operations:

  • Vertex Pharmaceuticals is a global biotechnology company focused on developing transformative medicines for people with serious diseases, with a focus on specialty markets
  • Key products include 4 approved medicines for cystic fibrosis (CF) and 1 approved therapy for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
  • Pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, pain, kidney disease, type 1 diabetes, and other rare diseases
  • Sells products globally, with the majority of revenues coming from the U.S. and ex-U.S. markets

Industry and Market Trends:

  • Highly competitive biotechnology industry with significant regulatory oversight and pricing/reimbursement challenges
  • Increasing focus on rare/specialty disease treatments and cell/genetic therapies
  • Evolving healthcare policies and pricing regulations, especially in the U.S., that could impact product pricing and access

Recent Events:

  • Received approvals for CASGEVY (gene-edited cell therapy) for SCD and TDT in multiple markets
  • Preparing for potential near-term launches of new CF and acute pain products
  • Acquired Alpine Immune Sciences for $5 billion to expand into autoimmune kidney diseases
  • Entered multiple new collaboration and licensing agreements to bolster pipeline

Risk Factors:

  • Ability to successfully develop, obtain approval, and commercialize new products and product candidates
  • Reliance on sales of CF medicines as primary revenue source
  • Potential safety issues or regulatory non-compliance with marketed products
  • Pricing pressure and reimbursement challenges for products
  • Ability to attract and retain skilled personnel
  • Cybersecurity and data privacy risks
  • Intellectual property disputes and patent expirations

Legal Matters:

  • No significant ongoing legal proceedings disclosed

Management's Discussion and Analysis:

  • Revenues primarily driven by strong performance of CF medicines, with TRIKAFTA/KAFTRIO as the key growth driver
  • Investing heavily in R&D, with a focus on advancing pipeline programs and expanding cell/genetic therapy capabilities
  • Maintaining strong liquidity position with $11.2 billion in cash and marketable securities as of Q1 2024
  • Gross margins around 85-87% in recent quarters, with cost of sales increasing due to CASGEVY launch
  • Effective tax rate fluctuates based on various factors, including acquisitions and collaborations
Earnings calls
Add to research
View more

Earnings Report 2024Q3 (2024-11-04)

Key takeaways
  1. Vertex is diversifying beyond CF: The successful launch of CASGEVY and upcoming launches in pain and potentially other therapeutic areas signal a significant shift towards a more diversified revenue base.
  2. Pipeline progress is driving future growth: The advancement of multiple programs into late-stage clinical trials, including promising therapies for diabetes, kidney disease, and pain, positions Vertex for continued growth in the coming years.
  3. Focus on non-opioid pain management: The development and potential launch of suzetrigine represent a significant opportunity to address the unmet need for effective non-opioid pain medications, with potential for substantial market penetration.
  4. Strategic investments in manufacturing and commercialization: Vertex is proactively investing in manufacturing capacity for CASGEVY and implementing strategic initiatives to ensure successful product launches, demonstrating a commitment to long-term growth.
  5. Positive regulatory interactions: Successful End-of-Phase 2 meetings for VX-880 and the evolving regulatory environment in renal disease suggest a favorable path forward for key pipeline programs.
Focus of management’s prepared remarks
  • Strong Q3 and Year-to-Date Performance: Vertex highlighted continued momentum in CF franchise and the successful early launch of CASGEVY, leading to increased full-year revenue guidance.
  • Pipeline Progress and Upcoming Launches: The company emphasized its "5-in-5" ambition, with potential launches of vanzacaftor triple for CF and suzetrigine for acute pain anticipated in early 2025. Several programs advanced to Phase 3 trials, including inaxaplin for kidney disease, suzetrigine for diabetic peripheral neuropathy, povetacicept for IgA nephropathy, and VX-880 for type 1 diabetes.
  • CF Franchise Growth: Reaching more patients and delivering $2.77 billion in revenue, representing 12% growth this quarter versus Q3 2023.
  • CASGEVY Launch Progress: Early launch success with high enthusiasm from patients and physicians, positive ATC and patient cell collection metrics, and recognition of first revenue.
  • VX-880 for Type 1 Diabetes: Completion of End-of-Phase 2 meetings with regulators and advancement to a pivotal Phase 1/2/3 study. Positive data presented at EASD showing insulin independence and elimination of severe hypoglycemic events in patients.
  • Povetacicept for IgA Nephropathy and other Renal Diseases: Initiation of the global Phase 3 RAINIER study, supported by positive Phase 2 data presented at ASN. Emerging positive data in primary membranous nephropathy.
  • Suzetrigine for Acute Pain: FDA review underway with PDUFA date of January 30, 2025. Positive feedback on Phase 3 data presented at the American Society of Anesthesiology meeting.
  • Pain Portfolio Expansion: Progress with next-generation NaV1.8 inhibitor VX-993 and preclinical advancement of NaV1.7 inhibitor program.
  • VX-670 for Myotonic Dystrophy Type 1: Acceleration of the program with completion of the single ascending dose portion and initiation of the multiple ascending dose portion of the Phase 1/2 study.
Focus of the analyst Q&A
  • Povetacicept Administration and At-Home Use: Questions regarding the at-home dosing profile for povetacicept and the necessary steps for approval, including potential human factors trials or bridging studies.
  • Suzetrigine in Lumbosacral Radiculopathy (LSR): Inquiries about the expected delta in NPRS score for suzetrigine versus baseline and placebo in the upcoming Phase 2 data readout, as well as confidence in the patient population definition for the trial. Comparison of suzetrigine's mechanism of action to Lyrica and its efficacy in LSR-related neuropathic pain.
  • Suzetrigine Pricing: Questions about the factors considered in pricing decisions for suzetrigine, including clinical benefit and unmet need.
  • VX-993 Benefits and Differentiation: Inquiries about the advantages of VX-993 compared to VX-548, beyond potency, and its potential role in combination therapies.
  • Inaxaplin in APOL1-Mediated Kidney Disease: Questions about the potential for filing based on UPCR at the one-year interim analysis, given the evolving regulatory environment. Also, inquiries about the potential market size and impact on the Vertex renal franchise.
  • CASGEVY Commercial Process and Patient Experience: Questions about learnings from the first commercial patient treated with CASGEVY, including administration process optimization and timing for dosing the next patient.
  • Suzetrigine Commercialization and Payer Discussions: Inquiries about the progress of contracting discussions with payers, their understanding of the need for non-opioid options, and other strategic initiatives beyond co-pay assistance programs.
Summary

  1. Financial Performance: Vertex Pharmaceuticals reported strong Q3 2024 results, with revenue growing 12% year-over-year to $2.77 billion. Year-to-date revenue reached $8.1 billion, a 10% increase compared to the same period in 2023. Q3 non-GAAP operating income was $1.31 billion, up from $1.17 billion in Q3 2023. The company ended the quarter with $11.2 billion in cash and investments.

  2. Revenue Drivers: Continued growth in cystic fibrosis (CF) product sales was the primary revenue driver, with $2 million recognized from the first commercial CASGEVY treatment. International CF sales growth outpaced US growth.

  3. Profit Margins and Cost Management: While specific margin figures weren't provided, operating expenses increased year-over-year due to investments in R&D and the commercial launch of CASGEVY and preparations for the suzetrigine launch. R&D expenses increased 5% year-over-year to $764 million, while SG&A expenses increased 39% to $300 million.

  4. Guidance and Outlook: Vertex raised its full-year 2024 product revenue guidance to $10.8 billion to $10.9 billion, reflecting continued strength in CF and early CASGEVY sales. Operating expense guidance remains unchanged at $4.2 billion to $4.3 billion. The company anticipates a non-GAAP full-year tax rate of approximately 90% due to the non-deductible Alpine Immune Sciences acquisition charge.

  5. Strategic Initiatives: Vertex is focused on expanding access to CASGEVY, including activating more treatment centers and securing payer coverage. The company is also preparing for the potential launch of vanzacaftor triple in CF and suzetrigine in acute pain in early 2025. Investment in additional manufacturing capacity for CASGEVY is underway. For suzetrigine, the company is focused on securing national retail distribution and establishing patient assistance programs.

  6. Management Commentary: Management expressed optimism about the company's performance and future prospects, highlighting strong commercial execution, pipeline progress, and the potential for new product launches. They emphasized the transformative potential of CASGEVY and suzetrigine.

  7. Industry and Market Conditions: Management noted the significant unmet need for effective pain management options, citing a survey highlighting concerns about opioid side effects and addiction potential. They also discussed the evolving regulatory environment in renal medicine, particularly for proteinuric kidney diseases.

Comparative analysis
Add to research
View more
Benchmarks (as of 2025-01-28)
Health Care Select Sector SPDR Fund (XLV)
  • Performance Comparison:
    • VRTX has exhibited a mixed performance history compared to XLV. While it has outperformed XLV over longer periods (2 years and 3 years), it has underperformed in the shorter periods (1 year, 6 months, 3 months, and 1 month). This suggests that VRTX's performance is not consistently better than XLV's.
    • VRTX's performance has been more volatile than XLV's, with periods of significant outperformance followed by periods of underperformance. This volatility may be attributed to VRTX's focus on a smaller number of drugs and its reliance on clinical trial outcomes.
  • Risk and Return Analysis:
    • VRTX has generally provided higher annualized returns than XLV over the past three years. However, this higher return has come with higher volatility.
    • VRTX has consistently exhibited higher annualized volatility than XLV, indicating that VRTX is a riskier investment. This higher volatility is likely due to VRTX's focus on a smaller number of drugs and its reliance on clinical trial outcomes.
    • VRTX has experienced a maximum drawdown of 23.24%, which is significantly higher than XLV's maximum drawdown of 16.06%. This suggests that VRTX is more susceptible to significant price declines than XLV.
  • Risk-Adjusted Performance:
    • VRTX has generally exhibited a lower Sharpe Ratio than XLV, indicating that VRTX has not been as efficient in generating risk-adjusted returns. This suggests that investors may be able to achieve better risk-adjusted returns by investing in XLV.
    • VRTX's beta value, while consistently below 1, has been slightly higher than XLV's beta, suggesting that VRTX is slightly more sensitive to market movements than XLV. This indicates that VRTX may be a slightly riskier investment than XLV.
  • Overall Assessment:
    • VRTX has shown potential for higher returns but comes with significantly higher risk compared to XLV. Its performance has been volatile, with periods of strong outperformance followed by periods of underperformance.
    • VRTX's higher volatility and larger drawdowns suggest that it is a riskier investment than XLV. While its Sharpe Ratio has been improving, it remains lower than XLV's, indicating that XLV may offer better risk-adjusted returns.
    • Investors seeking higher potential returns may consider VRTX, but they should be aware of the associated risks. Investors seeking a more stable and less volatile investment may prefer XLV.
Peers Price History(as of 2025-01-28)
Gilead Sciences, Inc. (GILD)Amgen, Inc. (AMGN)
  • Performance Comparison:
    • VRTX has generally outperformed GILD and AMGN over the long term, particularly in the 2-year and 3-year periods. However, VRTX has underperformed GILD in the short term, specifically in the 6-month and 1-year periods. This suggests that VRTX may be more volatile in the short term but has a stronger long-term growth potential.
  • Risk and Return Analysis:
    • VRTX has provided higher annualized returns than GILD and AMGN over the 2-year and 3-year periods. However, VRTX's annualized volatility has been higher than GILD's but lower than AMGN's. This indicates that VRTX has a higher risk profile than GILD but a lower risk profile than AMGN.
    • VRTX's maximum drawdown of 23.24% is lower than GILD's 26.59% but higher than AMGN's 24.86%. This suggests that VRTX's risk profile is moderate compared to its peers.
  • Risk-Adjusted Performance:
    • VRTX's Sharpe Ratio has generally been higher than GILD's and AMGN's, indicating that VRTX offers a better risk-adjusted return. This suggests that VRTX is able to generate higher returns for a given level of risk.
    • VRTX's beta has been consistently lower than AMGN's, indicating that VRTX is less sensitive to market movements than AMGN. This suggests that VRTX may be a more stable investment during periods of market volatility.
  • Overall Assessment:
    • VRTX appears to be a high-growth company with a moderate risk profile. Its strong long-term performance and higher risk-adjusted returns suggest that VRTX could be a valuable addition to a diversified portfolio. However, investors should be aware of VRTX's higher short-term volatility and potential for drawdowns.
    • VRTX's recent trends suggest that the company is continuing to grow and outperform its peers. Its Sharpe Ratio has been trending upward, indicating that its risk-adjusted returns are improving. However, investors should continue to monitor VRTX's volatility and drawdown characteristics.
Peers Fundamentals(as of 2024-09-30)
Gilead Sciences, Inc. (GILD)Amgen, Inc. (AMGN)

  1. Market Position and Size:

    • VRTX is a mid-sized company within its peer group, with a market capitalization larger than GILD but smaller than AMGN.
    • Despite its smaller market cap, VRTX has higher revenue than AMGN, suggesting a premium valuation.
    • VRTX's market cap is slightly larger than GILD's, despite having significantly lower revenue, indicating a higher valuation multiple.

  2. Profitability and Efficiency:

    • VRTX has a significantly higher gross profit margin than its peers, indicating efficient conversion of sales into gross profit.
    • However, VRTX's EBITDA margin, EBIT margin, and net profit margin are significantly lower than its peers and the industry average, due to high operating expenses, particularly in research and development.
    • VRTX's return on assets, return on equity, return on capital, and return on invested capital are all significantly lower than its peers and the industry average, reflecting its current unprofitability.

  3. Financial Health and Stability:

    • VRTX has a strong liquidity position, with a current ratio and quick ratio higher than its peers.
    • VRTX's debt position is very conservative, with a significantly lower debt-to-equity ratio than its peers and the industry average.
    • Overall, VRTX's financial health is characterized by strong liquidity and a conservative debt position, but its profitability and cash flow generation need to improve.

  4. Valuation and Market Perception:

    • VRTX is valued at a premium compared to its peers and the industry average, likely due to its focus on specialized therapies with high pricing power and its strong growth prospects.
    • The market perceives VRTX as a leader in its niche market, but its low profitability and negative cash flow generation raise concerns about its long-term sustainability.

  5. Cash Flow and Capital Management:

    • VRTX's cash flow generation is significantly lower than its peers, considering their respective market caps, due to its high operating expenses and investments in new therapies.
    • VRTX is investing less in capital assets than its peers, potentially due to its focus on research and development rather than physical infrastructure.

  6. Growth and Future Prospects:

    • VRTX shows consistently higher growth in sales/revenue, EBITDA, and free cash flow compared to the peer group average.
    • However, VRTX shows consistently lower growth in net income and basic earnings per share compared to the peer group average.
    • VRTX's 5-year CAGR for sales/revenue and free cash flow is significantly higher than its 3-year CAGR, indicating an acceleration in growth.
    • VRTX's 5-year CAGR for net income and basic earnings per share are significantly lower than its 3-year CAGR, indicating a deceleration in profitability growth.
    • VRTX's growth is concentrated in sales/revenue and free cash flow, while its profitability growth is lagging behind.
    • VRTX's growth profile is characterized by strong revenue and free cash flow growth, but lagging profitability growth.

  7. Potential for Investment:

    • VRTX presents an interesting investment opportunity for investors seeking exposure to a high-growth company with a strong market position.
    • Its focus on specialized therapies with high pricing power and its robust revenue growth are attractive features.
    • However, its low profitability and negative cash flow generation raise concerns about its ability to sustain its growth and generate returns for investors.

  8. Key Risks and Considerations:

    • VRTX's high operating expenses, particularly in research and development, are currently outweighing its revenue growth, resulting in low profitability and negative cash flow generation.
    • VRTX's growth is not yet translating into sustainable profitability, and its ability to improve its profitability and cash flow generation is uncertain.
    • VRTX's focus on specialized therapies may limit its market reach and expose it to competition from other companies developing similar therapies.

  9. Overall Assessment:

    • VRTX is a high-growth company with a strong financial foundation, but its profitability and cash flow generation need to improve to sustain its growth trajectory.
    • VRTX's focus on specialized therapies with high pricing power and its robust revenue growth are attractive features, but its low profitability and negative cash flow generation raise concerns about its ability to sustain its growth and generate returns for investors.
    • Investors should carefully consider VRTX's financial performance and its ability to improve its profitability and cash flow generation before making an investment decision.
Comparison metrics
Add to research
View more